Finally, using our in vivo model, we investigated the contribution of mast cells to the initiation of neutrophil recruitment and the promotion of corneal inflammation after injury. To determine this, we used a clinically relevant pharmacologic inhibitor, cromolyn sodium (MCi), to block mast cell activation.
23 MCi was topically administered to the ocular surface at −6, −3, and 0 hours and 3 hours after corneal injury. Corneas were harvested at 6 hours after injury. PBS-treated mice with corneal injury and naïve mice served as controls. Treatment with MCi significantly inhibited mast cell activation after corneal injury, as demonstrated by reduced levels of β-hexosaminidase in the corneas of MCi-treated mice compared with PBS-treated injured controls (
Fig. 5A). Notably, PBS-treated injured controls demonstrated elevated expression of CXCL2 mRNA relative to naïve mice, but treatment with MCi abrogated this effect (
Fig. 5B). A similar trend of CXCL2 protein expression was detected by ELISA analysis of corneal lysates (
Fig. 5C). Single cell suspensions of corneal tissue were prepared, and flow cytometry was performed. Corneal infiltration of CD11b
+Ly6G
+ neutrophils was significantly elevated in PBS-treated injured controls relative to naïve mice, but treatment with MCi repealed this effect (
Fig. 5D). The cytokines IL-1β and TNFα have been shown to be elevated in ocular surface inflammation.
12–14,24 Analysis of the expression of IL-1β and TNFα mRNA in our three groups by real-time PCR demonstrated significantly decreased expression of these proinflammatory cytokines in the corneas of MCi-treated mice compared with PBS-treated injured controls (
Figs. 5E,
5F). Additionally, we tested the direct effect of MCi on neutrophil migration using in vitro chemotaxis assays. Our data showed no difference in the frequencies of migrated neutrophils to a CXCL2 gradient between MCi-treated and PBS-treated control groups (increase from baseline migration; 45.1 ± 6.6% compared with 40.7 ± 5.7%, respectively), suggesting that MCi does not directly modulate neutrophil migration. Collectively, our in vivo data demonstrate that mast cell inhibition results in decreased CXCL2 expression, with a concomitant reduction in early neutrophil infiltration of the cornea and diminished inflammation.